An Unusual Protector-Protégé Strategy for the Biosynthesis of Purine Nucleoside Antibiotics.

Pan Wu,Dan Wan,Gudan Xu,Gui Wang,Hongmin Ma,Tingting Wang,Yaojie Gao,Jianzhao Qi,Xiaoxia Chen,Jian Zhu,Yong-Quan Li,Zixin Deng,Wenqing Chen
DOI: https://doi.org/10.1016/j.chembiol.2016.12.012
IF: 9.039
2017-01-01
Cell Chemical Biology
Abstract:Pentostatin (PTN, deoxycoformycin) and arabinofuranosyladenine (Ara-A, vidarabine) are purine nucleoside antibiotics used clinically to treat hematological cancers and human DNA virus infections, respectively. PTN has a 1,3-diazepine ring, and Ara-A is an adenosine analog with an intriguing epimerization at the C-20 hydroxyl group. However, the logic underlying the biosynthesis of these interesting molecules has long remained elusive. Here, we report that the biosynthesis of PTN and Ara-A employs an unusual protector-protege strategy. To our surprise, we determined that a single gene cluster governs PTN and Ara-A biosynthesis via two independent pathways. Moreover, we verified that PenB functions as a reversible oxidoreductase for the final step of PTN. Remarkably, we provided the first direct biochemical evidence that PTN can protect Ara-A from deamination by selective inhibition of the host adenosine deaminase. These findings expand our knowledge of natural product biosynthesis and open the way for target-directed genome mining of Ara-A/PTN-related antibiotics.
What problem does this paper attempt to address?